Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24891404 | 0.97 | HRH3 (0.48) | SIGMAR1CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL9927903 | 0.97 | HRH3 (0.48) | SIGMAR1CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL24891389 | 0.97 | HRH3 (0.48) | SIGMAR1CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL24891390 | 0.97 | HRH3 (0.48) | SIGMAR1CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL12555 | 0.97 | HRH3 (0.48) | SIGMAR1CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL9927905 | 0.94 | — | — | |
| SCHEMBL2231151 | 0.88 | PIM1 (0.42) | SIGMAR1 | |
| SCHEMBL1186740 | 0.88 | — | — | |
| SCHEMBL7649942 | 0.84 | HRH3 (0.52) | SIGMAR1CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL2920396 | 0.84 | CHKA (0.43) | SIGMAR1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2014-06-19 | — | — | US | claimed |
| EP-2725024-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-04-30 | — | — | EP | claimed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | claimed |
| US-6479672-B1 | Diastereoselective preparation of Michael adducts | MERCK & CO., INC. | 2002-11-12 | — | — | US | claimed |
| US-20240209138-A1 | PRODUCTION OF HARD POLYURETHANE OR POLYISOCYANURATE FOAM | EVONIK OPERATIONS GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024118887-A1 | N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-3524603-B1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2022-06-08 | — | — | EP | disclosed |
| EP-3995489-A2 | DISULFIDE COMPOUNDS FOR DELIVERY OF PHARMACEUTICAL AGENTS | Tufts University (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022093817-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3974423-A1 | INDOLE DERIVATIVE-CONTAINING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| WO-2021197467-A1 | MULTI-TARGET ANTI-TUMOR COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海华汇拓医药科技有限公司 | 2021-10-07 | — | — | WO | disclosed |
| US-7244752-B2 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-17 | — | — | US | disclosed |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | SURLERAUX DOMINIQUE LOUIS N G | 2007-06-14 | — | — | US | disclosed |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | SURLERAUX DOMINIQUE LOUIS N G | 2007-06-14 | — | — | US | disclosed |
| WO-2007045572-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006120251-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-11-16 | — | — | WO | disclosed |
| US-6479672-B1 | Diastereoselective preparation of Michael adducts | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| WO-2000061572-A1 | DIASTEREOSELECTIVE PREPARATION OF MICHAEL ADDUCTS | MERCK & CO., INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | PLA2G5, LTA4H, PLA2G4A | SIGMAR1 4568/4885CARM1 3258/4885PRMT6 3759/4885 |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | SIGMAR1 3168/4885CARM1 3898/4885PRMT6 4516/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | SIGMAR1 3982/4885CARM1 4157/4885PRMT6 3878/4885 |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | NR0B1, NR0B2, NR2C2 | SIGMAR1 669/4885CARM1 370/4885PRMT6 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.